Your browser doesn't support javascript.
loading
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse, Relinde I Y; Van Limbergen, Evert J; Oberije, Cary J G; Troost, Esther G C; Hadrup, Sine R; Dingemans, Anne-Marie C; Hendriks, Lizza E L; Eckert, Franziska; Hiley, Crispin; Dooms, Christophe; Lievens, Yolande; de Jong, Monique C; Bussink, Johan; Geets, Xavier; Valentini, Vincenzo; Elia, Giuliano; Neri, Dario; Billiet, Charlotte; Abdollahi, Amir; Pasquier, David; Boisselier, Pierre; Yaromina, Ala; De Ruysscher, Dirk; Dubois, Ludwig J; Lambin, Philippe.
Afiliación
  • Lieverse RIY; The D-Lab and The M-Lab, Department of Precision Medicine, GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. relinde.lieverse@maastrichtuniversity.nl.
  • Van Limbergen EJ; Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Oberije CJG; The D-Lab and The M-Lab, Department of Precision Medicine, GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
  • Troost EGC; Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus at Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
  • Hadrup SR; OncoRay, National Center for Radiation Research in Oncology, Dresden, Germany.
  • Dingemans AC; Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
  • Hendriks LEL; Department of Pulmonary Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands.
  • Eckert F; Department of Pulmonary Diseases, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Hiley C; Department of Pulmonary Diseases, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands.
  • Dooms C; Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany.
  • Lievens Y; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6DD, UK.
  • de Jong MC; Department of Respiratory Diseases, Respiratory Oncology Unit, University Hospitals KU Leuven, Leuven, Belgium.
  • Bussink J; Department of Radiation Oncology, Ghent University Hospital and Ghent University, Ghent, Belgium.
  • Geets X; Department of Radiation Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, Amsterdam, CX, The Netherlands.
  • Valentini V; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Elia G; Department of Radiation Oncology, Cliniques Universitaires Saint-Luc, MIRO - IREC Lab, UCL, Bruxelles, Belgium.
  • Neri D; Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
  • Billiet C; Università Cattolica del Sacro Cuore, Istituto di Radiologia, Roma, Italy.
  • Abdollahi A; Philochem AG, Libernstrasse 3, CH-8112, Otelfingen, Switzerland.
  • Pasquier D; Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
  • Boisselier P; Department of Radiation Oncology, Iridium Network, Wilrijk (Antwerp), Belgium.
  • Yaromina A; University of Antwerp, Faculty of Medicine and Health Sciences, Campus Drie Eiken, Building S, Universiteitsplein 1, 2610 Wilrijk-Antwerp, Belgium.
  • De Ruysscher D; Division of Molecular and Translational Radiation Oncology, Department of Radiation Oncology, Heidelberg Faculty of Medicine (MFHD) and Heidelberg University Hospital (UKHD), Heidelberg Ion-Beam Therapy Center (HIT), 69120 Heidelberg, Germany.
  • Dubois LJ; Clinical Cooperation Unit Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital (UKHD) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Lambin P; German Cancer Consortium (DKTK) Core Center, Heidelberg, Germany.
BMC Cancer ; 20(1): 557, 2020 Jun 15.
Article en En | MEDLINE | ID: mdl-32539805
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Proteínas Recombinantes de Fusión / Radiocirugia / Carcinoma de Pulmón de Células no Pequeñas / Quimioradioterapia / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Proteínas Recombinantes de Fusión / Radiocirugia / Carcinoma de Pulmón de Células no Pequeñas / Quimioradioterapia / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Guideline Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: BMC Cancer Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos